MRK FDA Tuesday, November 3, 2026 +0.20 Positive

Merck Initiates Its ENHANCE-3 Phase 3 Randomized Clinical Trial Evaluating OHTUVAYRE For The Prevention Of Chronic Obstructive Pulmonary Disease

AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed